The invention relates to a process for preparation of compounds of formula (6) and (7), key intermediates for preparation of Osimetrtinib, compound of formula (1).
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
2.
CRYSTALLINE FORMS OF ACALABRUTINIB HYDROGEN MALEATE
The invention relates to mixed ethanol water solvate and methanol solvate of Acalabrutinib hydrogen maleate, compound of formula (1), solid forms thereof and processes for preparation thereof.
The invention relates to solid forms of Cabozantinib, compound of formula (1), salt with L-(+)-tartaric acid and processes for preparation thereof,
The invention relates to solid forms of Cabozantinib, compound of formula (1), salt with L-(+)-tartaric acid and processes for preparation thereof,
The invention deals with a novel process for preparation of the pharmaceutically useful product Osimertinib of formula (1).
The invention deals with a novel process for preparation of the pharmaceutically useful product Osimertinib of formula (1).
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention relates to a tablet composition comprising Ibrutinib and one ore more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinaemia (WM) and chronic graft versus host disease (cGVHD).
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
The present invention relates to a tablet composition comprising a granulate consisting of a co-precipitate on a substrate, wherein the co-precipitate comprises enzalutamide in amorphous form and a cellulosic concentration enhancing polymer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of castration-resistant prostate cancer.
A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
A61J 3/10 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
The present invention relates to a monolithic tablet composition for oral administration of tofacitinib, or a pharmaceutically acceptable salt thereof.
The present invention relates to process for preparing Melflufen, compound of formula (1) or a salt thereof, and to intermediates used in the process and solid forms thereof.
The present invention relates to process for preparing Melflufen, compound of formula (1) or a salt thereof, and to intermediates used in the process and solid forms thereof.
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
The present invention relates to a pharmaceutical granulate composition comprising Palbociclib free base with a high surface area having improving processability.
The present invention relates to a pharmaceutical granulate composition comprising Palbociclib free base with a high surface area having improving processability.
The invention relates to the tablet composition comprising edoxaban obtained by the direct compression process comprising the step of co-blending edoxaban and first portion of mannitol, wherein the weight ratio of edoxaban and first portion of mannitol is from 1:1 to 1:2.5.
The presented invention relates to a process for preparation of Cabozantinib, compound of formula (1), or Tivozanib, compound of formula (10) or a salr or a solvate thereof: Formula (1); Formula (10).
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07C 235/74 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
The present invention relates to a stable pharmaceutical formulation comprising obeticholic acid in a primary packaging, wherein the primary packaging further comprises adsorbing material. The formulation is preferably in the form of tablets for oral administration.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
The application relates to the crystalline Form 1S of Asciminib hydrochloride and processes for the preparation thereof. Also described are solvates of Asciminib with 2-butanol, isobutanol, tert- butanol, 2-methyl tetra hydrofuran and cyclohexanol from which the crystalline Form 1S of Asciminib hydrochloride can be prepared.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 35/02 - Antineoplastic agents specific for leukemia
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
17.
CAPILLARY GEL ELECTROPHORESIS SEPARATION OF DIASTEREOMERS OF PHOSPHOROTHIOATED OLIGONUCLEOTIDES
Method of identification and/or characterization of diastereomers mixtures of phosphorothioate oligonucleotides by capillary gel electrophoresis with a background electrolyte that has a pH 6 to 8, comprising the steps of: a) Preparing a gel matrix by dissolving a water soluble polymer containing a side chain having a functional group that interacts with diastereomers mixture to be analysed in a background electrolyte; b) Introducing the gel matrix in the capillary; c) Introducing the sample of diastereomers mixture of phosphorothioate to capillary; d) Applying an electric field greater than 200 volts/cm of capillary across the gel matrix in the capillary; e) Detecting the individual diastereomers and/or the characteristic groups of partially separated diastereomers of phosphorothioate oligonucleotides.
The presented invention relates to a process for preparation of Ibrutinib, comprising: a. Reacting compound of Formula (2) with compound of Formula (3) in a presence of Lewis acid to provide compound of Formula (4); b. Contacting compound of Formula (4) with toluene; c. Isolate a solid form of compound of Formula (4); d. Transforming compound of Formula (4) into Ibrutinib.
The presented invention relates to a process for preparation of Ibrutinib, comprising: a. Reacting compound of Formula (2) with compound of Formula (3) in a presence of Lewis acid to provide compound of Formula (4); b. Contacting compound of Formula (4) with toluene; c. Isolate a solid form of compound of Formula (4); d. Transforming compound of Formula (4) into Ibrutinib.
The present invention relates to a monolithic tablet composition for oral administration of tofacitinib or a pharmaceutically acceptable salt thereof, without a functional coating.
The present invention relates to a process for preparation of palbociclib, compound of formula (1) or a salt thereof,
wherein an intermediate, compound (2), is formed by reacting a compound of formula (3) and a compound of formula (4) in a solvent mixture comprising methanol and butanol:
The intermediate (2) can be transformed into palbociclib or a salt thereof.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
The invention relates to solid forms of Copanlisib hydrogen phosphate salt or Copanlisib fumarate salt or Copanlisib ditosylate salt or Copanlisib hydrogen citrate salt or Copanlisib maleate salt or Copanlisib malate salt or Copanlisib tartrate salt or Copanlisib dilactate salt or Copanlisib diacetate salt or Copanlisib dihydrochloride salt.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
35 - Advertising and business services
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Pharmaceutical preparations, substances and compositions;
biological and biochemical drug and cultures for medical
use; pharmaceutical active substances; pharmaceutical
components and ingredients. Surgical and medical devices, apparatus and instruments;
orthopedic articles; injection apparatus for medical
purposes. Office functions relating to the registration of
pharmaceutical preparations; compiling registration files,
for others; procurement of contracts for others; commercial
administration of the licensing of goods; advertising,
marketing and promotional services for the sale of
pharmaceutical drugs, pharmaceutical preparations and
medical devices; retail and wholesale services for
pharmaceutical drugs, pharmaceutical preparations and
medical devices; retail and online sale of pharmaceutical
drugs, pharmaceutical preparations and medical devices. Treatment of materials, including on request, for others,
for the purpose of manufacturing pharmaceutical and
biopharmaceutical preparations; manufacture, for others, of
pharmaceutical and biopharmaceutical preparations and raw
materials for the pharmaceutical industry. Consulting services in the field of pharmaceutical research;
biomedical research services; chemistry and biology
laboratories; scientific laboratory services; pharmaceutical
research and development in the pharmaceutical field;
information relating to medical and scientific research in
the field of pharmaceutical preparations; providing
information on the results of clinical trials for
pharmaceutical preparations; quality control of products for
the purpose of certification; laboratory research and
laboratory analysis; research and design for the
pharmaceutical industry; research and development of new
products for others; drug discovery testing in the context
of quality control; conducting clinical trials for
pharmaceutical preparations; conducting quality control of
pharmaceutical preparations; providing information and data
relating to medical research and developments; scientific
and medical research and development; development of
medicines to be sold by and under the trademark of third
parties; development of pharmaceutical ingredients for the
pharmaceutical industry. Legal services relating to obtaining pharmaceutical
registrations and compiling pharmaceutical registration
files; management of industrial property and copyright by
means of license agreements (legal services); licensing of
intellectual property; management of industrial property and
copyright by issuing licenses to others (legal services);
legal extensions relating to the retention of intellectual
property, for others; legal advice in the field of
intellectual property.
The present invention relates to a coated tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, characterized in that: ⋅Ibmtinib is form C, having characteristic peaks in the X-ray powder diffraction pattern at the following 2 theta (±0.2) angles: 6.9°, 18.2°, 19.2°, 19.6° and 23.0°, measured using a Cu Kα radiation; and ⋅The coating is free of plasticizer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinaemia (WM) and chronic graft-versus-host disease (cGVHD).
The presented invention relates to a process for preparation of Apalutamide, compound (1) (Formula 1) or a salt or a solvate thereof: The presented invention further relates to solid forms of Apalutamide, solvates of Apalutamide and to processes for preparation thereof. The presented invention also relates to solid forms of intermediates used in the process for preparing Compound (1).
The presented invention relates to a process for preparation of Apalutamide, compound (1) (Formula 1) or a salt or a solvate thereof: The presented invention further relates to solid forms of Apalutamide, solvates of Apalutamide and to processes for preparation thereof. The presented invention also relates to solid forms of intermediates used in the process for preparing Compound (1).
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07C 229/48 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
28.
CABOZANTINIB SALT WITH L-(+)-TARTARIC ACID AND SOLID FORMS THEREOF
The invention relates to Alectinib, compound of formula (1), solid forms thereof, salts thereof, solid forms of the salts and processes for preparation thereof,.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The presented invention relates to crystalline form, Form A of Ozanimod hydrochloride, processes for preparation thereof and pharmaceutical compositions comprising the Ozanimod hydrochloride Form A.
The present invention relates to a tablet composition comprising Ibrutinib and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), Waldenstrӧm's macroglobulinaemia (WM) and chronic graft versus host disease (cGVHD).
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
37.
CRYSTALLINE FORMS OF TAFAMIDIS NICOTINAMIDE ADDUCT
The presented invention relates to Tafamidis nicotinamide adduct, solid form thereof, crystalline form thereof, processes for preparation thereof and a composition comprising it.
The presented invention relates to crystalline Forms (I) or (II) or (III) or (IV) of sodium salt of Bempedoic acid, processes for preparation thereof and a composition comprising it.
The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising calcium silicate as diluent. The invention further relates to the use of said tablet as a medicament, particularly in the treatment of immune thrombocytopenia (ITP), thrombocytopenia in patients with chronic hepatitis C virus (HCV) and severe aplastic anaemia (SAA).
The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising maltose and isomalt as diluents. The invention further relates to the use of said tablet as a medicament, particularly in the treatment of immune thrombocytopenia (ITP), thrombocytopenia inpatients with chronic hepatitis C virus (HCV) and severe aplastic anaemia (SAA).
The present invention relates to a monolithic tablet composition for oral administration of tofacitinib, or a pharmaceutically acceptable salt thereof.
The present invention relates to process for preparing Melflufen, compound of formula (1) or a salt thereof, and to intermediates used in the process and solid forms thereof.
The present invention relates to a monolithic tablet composition for oral administration of tofacitinib, or a pharmaceutically acceptable salt thereof.
The present invention relates to a tablet composition comprising a granulate consisting of a co-precipitate on a substrate, wherein the co-precipitate comprises enzalutamide in amorphous form and a cellulosic concentration enhancing polymer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of castration-resistant prostate cancer.
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61J 3/10 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
The presented invention relates to crystalline Form A and Form B of Bempedoic acid, a process for preparation thereof and a composition comprising the Form A or Form B.
The presented invention relates to Omecamtiv mecarbil salts with methane sulfonic acid, benzene sulfonic acid and p-toluene sulfonic acid and to processes for preparation thereof.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The presented invention relates to a lyophilized pharmaceutical formulation comprising copanlisib salt and a bulking agent selected from lactose or trehalose and to a process for preparation thereof.
The present invention relates to the process of preparation of salts of compound of formula (1).
The present invention relates to the process of preparation of salts of compound of formula (1).
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention relates to the process of preparation of compound of formula (I) or a salt thereof. Further it relates to the solid form of compound (I).
The presented invention relates to a process for preparation of Enzalutamide, compound (1) or a salt or a solvate thereof Formula (1). The presented invention also related to 1,4-dioxane solvate of compound (1).
The presented invention relates to a process for preparation of Enzalutamide, compound (1) or a salt or a solvate thereof Formula (1). The presented invention also related to 1,4-dioxane solvate of compound (1).
The presented invention relates to a process for preparation of Ibrutinib, comprising: a. Reacting compound of Formula (2) with compound of Formula (3) in a presence of Lewis acid to provide compound of Formula (4); b. Contacting compound of Formula (4) with toluene; c. Isolate a solid form of compound of Formula (4); d. Transforming compound of Formula (4) into Ibrutinib.
The present invention relates to an immediate release tablet composition comprising axitinib form IV characterized by an XRPD pattern comprising the peaks at about 8.9, 12.0, 14.6, 15.2, 15.7, 17.8, 19.1, 20.6, 21.6, 23.2, 24.2, 24.9, 26.1 and 27.5±0.1 degrees 2θ, when measured with Cu Kα1 radiation and one or more pharmaceutically acceptable excipients, wherein the composition exhibits a dissolution rate between 40% and 70% in 30 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 at 37° C., 75 rpm in a USP apparatus II.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The presented invention relates to a process for preparation of compound of formula (I) or a salt or a solvate thereof (i.e.) siponimod. The invention also relates to intermediates used in the process and solid forms of these intermediates.
The presented invention relates to a process for preparation of compound of formula (I) or a salt or a solvate thereof (i.e.) siponimod. The invention also relates to intermediates used in the process and solid forms of these intermediates.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07C 17/16 - Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
C07C 249/08 - Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds
C07C 249/12 - Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reactions not involving the formation of oxyimino groups
C07C 303/28 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
1) A process for preparing Axitinib (N-methyl-2-({3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl}sulfanyl)benzamide; compound of formula (I)) 2) A process for purifying the intermediate 2-((3-iodo-1H-indazol-6-yl)thio)-N-methylbenzamide (compound of formula (IIa)) 3) A process for purifying Axitinib using the Axitinib HCI salt (compound of formula (VIII)) as an intermediate 4) A solid form of the Axitinib HCI salt (form J) characterized by an XRPD pattern
1) A process for preparing Axitinib (N-methyl-2-({3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl}sulfanyl)benzamide; compound of formula (I)) 2) A process for purifying the intermediate 2-((3-iodo-1H-indazol-6-yl)thio)-N-methylbenzamide (compound of formula (IIa)) 3) A process for purifying Axitinib using the Axitinib HCI salt (compound of formula (VIII)) as an intermediate 4) A solid form of the Axitinib HCI salt (form J) characterized by an XRPD pattern
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The presented invention relates to Baloxavir, salts of Baloxavir, cocrystals of Baloxavir, to solid forms of thereof and to processes for preparation thereof.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61P 37/00 - Drugs for immunological or allergic disorders
The presented invention relates to a process for preparation of Apalutamide, compound (1) (Formula 1) or a salt or a solvate thereof: The presented invention further relates to solid forms of Apalutamide, solvates of Apalutamide and to processes for preparation thereof. The presented invention also relates to solid forms of intermediates used in the process for preparing Compound (1).
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07C 229/48 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms of the same non-condensed ring
60.
Crystalline forms and processes of lenvatinib besylate
The present invention relates to lenvatinib besylate, its crystalline forms and processes for making them. Furthermore, to a pharmaceutical composition comprising a therapeutically effective dose of lenvatinib besylate.
The present invention relates to a coated tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, characterized in that: • Ibrutinib is form C, having characteristic peaks in the X-ray powder diffraction pattern at the following 2 theta (± 0.2) angles: 6.9º, 18.2º, 19.2º, 19.6º and 23.0º, measured using a Cu Kα radiation; and • The coating is free of plasticizer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), Waldenstrӧm's macroglobulinaemia (WM) and chronic graft-versus-host disease (cGVHD).
The present invention relates to an immediate release tablet composition comprising free particles of ivacaftor a pH dependent polymer and surfactant extragranularly and intragranularly.
C07C 59/245 - Saturated compounds having more than one carboxyl group containing hydroxy or O-metal groups
C07D 295/027 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
C07C 215/08 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
The presented invention relates to a process for preparation of compound of formula (1) or a salt thereof (i.e.) ozanimod: (1). The invention also relates to intermediates used in the process.
C07D 263/22 - Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
The presented invention relates to crystalline form, Form A of Ozanimod hydrochloride, processes for preparation thereof and pharmaceutical compositions comprising the Ozanimod hydrochloride Form A.
The present invention relates to pharmaceutical compositions comprising a therapeutically effective dose of elagolix sodium and pharmaceutically acceptable excipients comprising a super disintegrant. The compositions can further comprise an alkalizer and/or a non-ionic surfactant.
The present invention related to a process for preparation of compound of formula (1) or a salt thereof (i.e.) palbociclib: The invention also relates to a solid crystalline form of intermediate of formula (2) used in the process:
The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising maltose and isomalt as diluents. The invention further relates to the use of said tablet as a medicament, particularly in the treatment of immune thrombocytopenia (ITP), thrombocytopenia in patients with chronic hepatitis C virus (HCV) and severe aplastic anaemia (SAA).
The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising calcium silicate as diluent. The invention further relates to the use of said tablet as a medicament, particularly in the treatment of immune thrombocytopenia (ITP), thrombocytopenia in patients with chronic hepatitis C virus (HCV) and severe aplastic anaemia (SAA).
The presented invention relates to crystalline Forms (I) or (II) or (III) or (IV) of sodium salt of Bempedoic acid, processes for preparation thereof and a composition comprising it.
The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising calcium silicate as diluent. The invention further relates to the use of said tablet as a medicament, particularly in the treatment of immune thrombocytopenia (ITP), thrombocytopenia in patients with chronic hepatitis C virus (HCV) and severe aplastic anaemia (SAA).
The present invention relates to a tablet composition comprising a granulate consisting of a co-precipitate on a substrate, wherein the co-precipitate comprises enzalutamide in amorphous form and a cellulosic concentration enhancing polymer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of castration-resistant prostate cancer.
The present invention relates to a tablet composition comprising a granulate consisting of a co-precipitate on a substrate, wherein the co-precipitate comprises enzalutamide in amorphous form and a cellulosic concentration enhancing polymer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of castration-resistant prostate cancer.
The presented invention relates to crystalline Form A and Form B of Bempedoic acid, a process for preparation thereof and a composition comprising the Form A or Form B.
The presented invention relates to Omecamtiv mecarbil salts with methane sulfonic acid, benzene sulfonic acid and p-toluene sulfonic acid and to processes for preparation thereof.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
78.
SALTS OF OMECAMTIV MECARBIL AND SOLID FORMS THEREOF
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
79.
ISAVUCONAZONIUM SALTS AND PROCESS FOR PREPARING THEREOF
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present invention relates to a monolithic tablet composition for oral administration of tofacitinib, or a pharmaceutically acceptable salt thereof.
The present invention relates to a tablet composition for oral administration of abiraterone acetate, particularly to pharmaceutical granulates and tablets giving immediate release of abiraterone acetate in the stomach.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The present invention relates to the process of preparation of compound of formula (I) or a salt thereof. Further it relates to the solid form of compound (I).
The presented invention relates to a process for preparation of Enzalutamide, compound (1) or a salt or a solvate thereof Formula (1). The presented invention also related to 1,4-dioxane solvate of compound (1).
The presented invention relates to a process for preparation of Enzalutamide, compound (1) or a salt or a solvate thereof Formula (1). The presented invention also related to 1,4-dioxane solvate of compound (1).
The presented invention relates to salts of Siponimod with Fumaric acid (1:1) and solid Forms 1 and 2 thereof. The presented invention further relates to salts of Siponimod with Maleic acid (1:1) and solid Forms 1, 2, 3, 4, 5, 6, 7, 8 and 9 thereof.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
The present invention relates to an immediate release tablet composition comprising axitinib form IV characterized by an XRPD pattern comprising the peaks at about 8.9, 12.0, 14.6, 15.2, 15.7, 17.8, 19.1, 20.6, 21.6, 23.2, 24.2, 24.9, 26.1 and 27.5 ± 0.1 degrees 2θ, when measured with Cu Kα1 radiation and one or more pharmaceutically acceptable excipients, wherein the composition exhibits a dissolution rate between 40% and 70% in 30 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 at 37ºC, 75 rpm in a USP apparatus II.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present invention relates to a pharmaceutical composition comprising a solid dispersion of sunitinib L-malate and polyvinylpyrrolidone in a primary packaging comprising means to absorb water. The invention further relates to the use of said composition as a medicament, particularly in the treatment of a tyrosine kinase-related disorder.
A61J 1/00 - Containers specially adapted for medical or pharmaceutical purposes
88.
PROCESS FOR PREPARING AXITINIB, PROCESS FOR PURIFYING THE INTERMEDIATE 2-((3-IODO-1H-INDAZOL-6-YL)THIO)-N-METHYLBENZAMIDE, PROCESS FOR PURIFYING AXITINIB VIA THE AXITINIB HCL SALT, SOLID FORM OF THE AXITINIB HCL SALT
1) A process for preparing Axitinib ( N-methyl-2-({3-[(E)-2-pyridin-2- ylethenyl]-lH-indazol-6-yl}sulfanyl)benzamide; compound of formula (l)) 2) A process for purifying the intermediate 2-((3-iodo-lH-indazol-6- yl)thio)-N-methylbenzamide (compound of formula (lla)) 3) A process for purifying Axitinib using the Axitinib HCI salt (compound of formula (VIII)) as an intermediate 4) A solid form of the Axitinib HCI salt (form J) characterized by an XRPD pattern
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present invention relates to solid Form 1, Form 2, Form 3 and Form 6 of the compound Siponimod and processes for preparation thereof. The present invention further relates to processes for preparation of solid Form A of the compound Siponimod.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
90.
PROCESS FOR MAKING SIPONIMOD AND INTERMEDIATE THEREOF
The presented invention relates to a process for preparation of compound of formula (I) or a salt or a solvate thereof (i.e.) siponimod. The invention also relates to intermediates used in the process and solid forms of these intermediates.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
The present invention relates to a tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, characterized in that: • Ibrutinib is form C, having characteristic peaks in the X-ray powder diffraction pattern at the following 2 theta (±0.2) angles: 6.9º, 18.2º, 19.2º, 19.6º and 23.0º, measured using a Cu Kα radiation; and • Ibrutinib form C is present in an amount from 60 to 80% w/w relative to the total weight of the tablet; and • The composition is free of surfactant; and • The composition exhibits a dissolution rate of at least 65% in 20 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 (+1% Tween 20) at 37ºC, 75 rpm and/or in 900 ml phosphate buffer pH 6.8 (+3% Tween 20) at 37ºC, 75 rpm in a USP apparatus II. The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenstrӧm's macroglobulinaemia (WM).
the composition exhibits a dissolution rate of at least 65% in 20 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 (+1% Tween 20) at 37° C., 75 rpm and/or in 900 ml phosphate buffer pH 6.8 (+3% Tween 20) at 37° C., 75 rpm in a USP apparatus II.
The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinaemia (WM).
The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1:1.5 to 1:5.
The presented invention relates to a process for preparation of compound of formula (1) or a salt thereof (i.e.) ozanimod : (1). The invention also relates to intermediates used in the process.
The present invention relates to lenvatinib besylate, its crystalline forms and processes for making them. Furthermore, to a pharmaceutical composition comprising a therapeutically effective dose of lenvatinib besylate.
The present invention relates to lenvatinib besylate, its crystalline forms and processes for making them. Furthermore, to a pharmaceutical composition comprising a therapeutically effective dose of lenvatinib besylate.
The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of lenvatinib esylate or tosylate having sodium wherein the weight ratio of lenvatinib esylate or tosylate to sodium carbonates ranges from 1:.5 to 1:10.
The present invention relates to a tablet into tablet composition for oral administration of tofacitinib, or a pharmaceutically acceptable salt thereof.
